https://www.selleckchem.com/products/ca3.html
To confirm the efficacy and safety of dasiglucagon when administered via an autoinjector device. In this double-blind trial, 45 participants with type 1 diabetes were randomized 31 to receive a single subcutaneous dose of dasiglucagon 0.6mg or placebo following controlled induction of hypoglycaemia. The primary endpoint was time to plasma glucose recovery, defined as a plasma glucose increase of 20 mg/dL or higher from baseline without rescue intravenous glucose. Median (95% CI) observed time to recovery was 10.0 (8.0; 12. minutes for das
Like
Comment
Share
